The impact of obesity medication on fat-free mass and physical function

Uncovering the impact of incretins on fat-free mass, muscle strength and functionalcapacity - Impact of GLP-1 RAs on body composition and physical function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58608

Enrollment

200

Registered

2025-11-21

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Excess body fat

Interventions

Given the observational nature of this study, no intervention will take place.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Screened and planned to start with incretin treatment or currently using incretin treatment and planned to discontinue treatmentAged 18 years or older

Exclusion criteria

Exclusion criteria: Inability to comprehend scheduled procedures (e.g., language barriers)Unable to perform the physical tests due to physical disabilitiesPatients who underwent metabolic and bariatric surgeryPrior use of incretins, or other obesity medication

Design outcomes

Primary

Measure	Time frame
The primary outcome of this study is the composition of weight loss (the ratio of FFM to total weight loss) after 12 months of GLP-1 RA therapy in the START-group, and the composition of recurrent weight gain (the ratio of FFM to recurrent weight gain) after 12 months of discontinuing GLP-1 RA therapy in the STOP-group.	—

Secondary

Measure	Time frame
Secondary outcomes of this study are muscle strength and functional capacity.	—

Countries

Netherlands

Contacts

Public ContactJ.H.M. Karregat

Radboud Universitair Medisch Centrum

jan.karregat@radboudumc.nl(+31) 653461919

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 22, 2026